Executive Management Board

The CEO and, under his direction, the other EMB members are responsible for the Group’s overall business and day-to-day management. The EMB is also responsible for the implementation of strategic decisions and stakeholder management. The CEO reports to the Board regularly and whenever extraordinary circumstances so require. Each member of the EMB is appointed and discharged by the Board of Directors.

The EMB comprises 14 members under the leadership of, and including, the CEO, Guillaume Daniellot.

Other activities and vested interest

Marco Gadola is a Member of the Board of Calida Group (Chairman). In 2019, he was a Member of the Board of Mettler-Toledo International Inc. and since 2020, he is a Member of the Boards of DKSH Holding (Chairman) and Medacta Group. In addition, he is a Panel Member of the Swiss-American Chamber of Commerce.

Dr Gerhard Bauer is a Member of the Board of Swiss Medtech and a Member of the Board of siteminsel AG, Switzerland.

In 2019, Frank Hemm was a Member of the Board of Directors and Board of Trustees of the International Team for Implantology (ITI), an independent academic network supported by payments from Straumann under a collaboration agreement (see Note 9.4 of the Audited Consolidated Financial Statements on p. 180). He was succeeded in this capacity by Guillaume Daniellot on 1 January 2020.

Since 2017, Patrick Loh has been Chairman of the Essence & DM Dental Industry Investment Partnership, a private equity fund addressing the dental sector in China.

Dr Andreas Meier is a trustee of the ‘Schönes Lächeln’ Foundation, Switzerland, which is supported by payments from Straumann under a collaboration agreement.

Other than these, no member of the EMB:

  • performed any activities in governing or supervisory bodies of significant foreign or domestic organizations, institutions or foundations under private or public law
  • held any permanent management or consultancy function for significant domestic or foreign interest groups
  • held any official function or political post.

Permitted mandates outside Straumann (pursuent to art. 12 OAEC)

Art. 4.4 of Straumann’s Articles of Association states that no member of the EMB may perform more than five mandates (i.e. mandates in the highest level governing body of a legal entity required to be registered in the Commercial Register or in a corresponding foreign register) in commercial enterprises, of which no more than two may be in a listed company. The following are exempt from these restrictions:

  • Mandates in enterprises that control the Group or are controlled by the same
  • Mandates in enterprises that are performed at the instruction of the Group
  • Mandates in associations, organizations, and legal entities with a public or charitable purpose, and in foundations, trusts, and employee pension funds. No member of the Executive Management may perform more than three such mandates.

Mandates in several legal entities under common control or under the same economic authority are deemed as one mandate.

Management contracts

The Board of Directors and the EMB have not delegated any managerial powers to persons or companies outside the Group.

Changes of control and defense measures

The Articles of Association of Straumann Holding AG do not contain provisions for opting out or opting up. There are no change-of-control clauses included in agreements and schemes benefiting members of the Board of Directors or the Executive Management Board or other management staff.

Information and control mechanisms for the Board of Directors and the Executive Management Board

 

Management Information System

The Group’s Management Information System encompasses management, business and financial reporting. The information is provided to the Executive Management Board once a month and to the Board of Directors as a monthly summary and in detail on a quarterly basis.

Straumann operates a state-of-the-art SAP enterprise resource planning system, which covers 90% of all business transactions of the Group’s fully consolidated entities. The system links Group headquarters directly with all major subsidiary companies and production sites, including Brazil, which switched to SAP on 1 January 2019. ClearCorrect will be switched to SAP in the second quarter of 2020 and Anthogyr is due to follow early in 2022. This system greatly reduces the potential for error or fraud, and enables the Executive and Senior Management to monitor local processes and related figures directly, in detail and in real time.

In addition, the Board of Directors maintains close contact with the Executive Management and gains first-hand information through workshops, co-travel, site visits and participation in staff meetings.

 

Internal Control System

The Group’s Internal Control System (ICS) is a key instrument for designing business processes, measuring progress towards financial goals and addressing potential financial issues before they occur. It also supports the design of business processes in order to achieve the desired level of control in terms of efficiency and effectiveness. 

The company’s approach is to ensure that internal controls are accurate, timely, robust, and receive appropriate management attention in each respect. To achieve this, dedicated control templates are used for each business process to address major risks. The templates are continuously improved. 

In addition, each entity (sales affiliate, production site or global function) has a designated, trained person or team that is ultimately accountable for the assessment undertaken and the decisions arising from it. Clear benefits of the Internal Control System include enhanced segregation of duties, increased control consciousness and higher awareness of potential risks and their consequences.

The ICS program is coordinated by the Group CFO, who meets with the external auditors on a regular basis to discuss the status of internal control issues and the status of remediation of control deficiencies. Internal controls are evaluated annually by the external auditors and by Internal Audit according to an agreed program.

Internal Audit

The role of the Group’s Internal Audit function is to provide independent assurance to the Board of Directors that the key risks of the organization are under control and to support Management in ensuring compliance, operational efficiency and control effectiveness across the Group.

A highly experienced team at KPMG in Basel complemented by local KPMG offices with specific local language skills and expertise conducts the Internal Audits reporting to the Audit & Risk Committee. In 2019, five internal audits were performed at global and local levels according to the audit program approved by the Audit & Risk Committee of the Board of Directors.

Corporate Risk Management 

The Board of Directors is responsible for the overall supervision of risk management and uses the Internal Audit function to this end. The Board has delegated the task of risk management to the Chief Risk Officer (CRO). Through its Audit & Risk Committee, the Board assesses and discusses risks on a regular basis in consultation with the CRO and/or the relevant members of senior management (see p. 51 ff.).